Canakinumab
Canakinumab
Definition
A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation.
Also known as ACZ885, CANAKINUMAB, Ilaris — per NCIT
Also identified as
- ATC L04AC08 per RXNORM
- NCIT NCIT:C80971 per NCIT
- SCTID 698091001 per RXNORM
- SCTID 703376008 per RXNORM
- UNII 37CQ2C7X93 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Cryopyrin-associated periodic syndrome | may treat | MEDRT · Public domain (U.S. Government work) |
| Familial Mediterranean fever | may treat | MEDRT · Public domain (U.S. Government work) |
| Juvenile idiopathic arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone element | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Skeletal joint | may treat a disease of this organ | DERIVED · CC BY 4.0 |
3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.